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Postprandial release of the incretin glucagon-like pep-
tide-1 (GLP-1) has been suggested to act as an endoge-
nous satiety factor in humans. In rats, however, the
evidence for this is equivocal probably because of very
high endogenous activity of the GLP-1 degrading en-
zyme dipeptidyl peptidase-IV. In the present study, we
show that intravenously administered GLP-1 (100 and
500 g/kg) decreases food intake for 60 min in hungry
rats. This effect is pharmacologically speciﬁc as it is
inhibited by previous administration of 100 g/kg ex-
endin(9-39), and biologically inactive GLP-1(1-37) had
no effect on food intake when administered alone (500
g/kg). Acute intravenous administration of GLP-1 also
caused dose-dependent inhibition of water intake, and
this effect was equally well abolished by previous ad-
ministration of exendin(9-39). A profound increase in
diuresis was observed after intravenous administration
of both 100 and 500 g/kg GLP-1. Using a novel long-
acting injectable GLP-1 derivative, NN2211, the acute
and subchronic anorectic potentials of GLP-1 and deriv-
atives were studied in both normal rats and rats made
obese by neonatal monosodium glutamate treatment
(MSG). We showed previously that MSG-treated ani-
mals are insensitive to the anorectic effects of centrally
administered GLP-1(7-37). Both normal and MSG-
lesioned rats were randomly assigned to groups to
receive NN2211 or vehicle. A single bolus injection of
NN2211 caused profound dose-dependent inhibition of
overnight food and water intake and increased diuresis
in both normal and MSG-treated rats. Subchronic mul-
tiple dosing of NN2211 (200 g/kg) twice daily for 10
days to normal and MSG-treated rats caused profound
inhibition of food intake. The marked decrease in food
intake was accompanied by reduced body weight in both
groups, which at its lowest stabilized at 85% of initial
body weight. Initial excursions in water intake and
diuresis were transient as they were normalized within
a few days of treatment. Lowered plasma levels of
triglycerides and leptin were observed during NN2211
treatment in both normal and MSG-treated obese rats.
In a subsequent study, a 7-day NN2211 treatment period
of normal rats ended with measurement of energy ex-
penditure (EE) and body composition determined by
indirect calorimetry and dual energy X-ray absorptiom-
etry, respectively. Compared with vehicle-treated rats,
NN2211 and pair-fed rats decreased their total EE
corresponding to the observed weight loss, such that EE
per weight unit of lean body mass was unaffected.
Despite its initial impact on body ﬂuid balance, NN2211
had no debilitating effects on body water homeostasis as
conﬁrmed by analysis of body composition, plasma elec-
trolytes, and hematocrit. This is in contrast to pair-fed
animals, which displayed hemoconcentration and ten-
dency toward increased percentage of fat mass. The
present series of experiments show that GLP-1 is fully
capable of inhibiting food intake in rats via a peripher-
ally accessible site. The loss in body weight is accompa-
nied by decreased levels of circulating leptin indicative
of loss of body fat. The profound weight loss caused by
NN2211 treatment was without detrimental effects on
body water homeostasis. Thus, long-acting GLP-1 deriv-
atives may prove efﬁcient as weight-reducing therapeu-
tic agents for overweight patients with type 2 diabetes.
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eripheral administration of glucagon-like pep-
tide-1 (GLP-1) acutely affects food intake in hu-
mans, but the underlying mechanisms that
decrease food intake concomitant with earlier
onset of subjective sensation of fullness are not fully
understood (1–4). The anorectic effects of continuous
intravenous administration of GLP-1 are present in indi-
viduals who are lean or obese or have type 2 diabetes
(1,3,4), suggesting that the observed effects are part of a
physiologically relevant meal-terminating system. Results
from similar experiments in rats have been ambiguous,
probably because of high activity of GLP-1 degrading
enzyme dipeptidyl peptidase-IV (DPP-IV) (5,6). Thus, early
experiments were unable to demonstrate peripheral ef-
fects of intraperitoneal GLP-1 injections on feeding be-
havior (7,8), whereas later experiments have shown
signiﬁcant but short-lasting anorectic effects of subcuta-
neous administration of GLP-1 (9). Anorexia induced by
peripheral administration of GLP-1 involves vagal control
of gastric motility (10,11).
Central administration of 1–3 g of GLP-1 speciﬁcally
inhibits food intake in rats via a hypothalamic site that is
sensitive to neonatal monosodium glutamate (MSG) le-
sioning (12). However, central administration of slightly
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this latter effect is unaffected by MSG treatment, it further
stresses the speciﬁcity of the central GLP-1–induced an-
orexia (12). In addition, it is possible to elicit anorexia
without concomitant taste aversion if GLP-1 is injected
directly into the hypothalamic paraventricular nucleus
(13). Acute injections of both GLP-1 and NN2211 exerts
profound adipsia and diuresis. These effects on body water
homeostasis could potentially hamper long-term treatment
of patients with type 2 diabetes with GLP-1 agonists, and
the potential anorectic effects of these agonists may be
accompanied with debilitating affects on body water ho-
meostasis.
Given that peripheral administration of GLP-1 affects
food intake in humans, we decided to study further the
anorectic potential of this peptide in the laboratory rat.
Dose-response studies investigating the effect of intrave-
nously administered GLP-1(7-37) or a novel long-acting
acylated GLP-1 derivative NN2211 (14) on food intake
were performed. In continuation of acute pharmacological
studies, we examined the effect on food intake and body
weight of twice daily subcutaneous administration of
NN2211 for 10 days followed by a 5-day recovery period.
To study the impact of 7 days of NN2211 treatment on
energy expenditure (EE) and body composition, we stud-
ied normal rats by indirect calorimetry and subsequently
subjected them to dual energy X-ray absorptiometry
(DEXA) scanning. Before, during, and after treatment,
blood biochemical markers of energy and ﬂuid homeosta-
sis metabolic state were monitored.
RESEARCH DESIGN AND METHODS
Animals. All experiments were carried out on male Wistar rats. Normal male
rats arrived at the animal facilities 2 weeks before experimentation, and until
use, animals were housed three to four per cage under standard laboratory
conditions (12:12 light:dark cycle, lights on 6:00 A.M.). Before experimentation,
animals had free access to a standard rat diet (Altromin 1324) and water ad
libitum. Hypothalamically obese rats were obtained by treating neonatal rats
with MSG. Pregnant Wistar rats (Møllegården, Ll; Skensved, Denmark) arrived
at the animal unit 1 day before timed labor (E21). Neonatal Wistar pups
received a number of subcutaneous injections with MSG (L-glutamic acid,
G-1626; 4 mg/g body wt; Sigma, Vallensbaek Strand, Denmark) dissolved in
sterile distilled H2O. Injections were given at days P1, P3, P5, P7, and P9
according to a previously published method (12). After weaning, pups were
separated by sex and allowed to grow to the age of 12–14 weeks before
experiments were initiated. Neonatal MSG treatment is accompanied by adult
obesity and a number of neuroendocrine dysfunctions (hypothalamic hypo-
gonadism, low fertility, stunted growth, chronic HPA-axis activation), and
currently used MSG-treated rats all displayed characteristic stunted growth,
adiposity, short tail caused by self-mutilation, and apparent blindness. All
experiments were carried out in accordance with guidelines provided by the
Danish Justice Department and approved by a personal license to P.J.L.
Formulation of GLP-1(7-37), GLP-1(1-37), exendin(9-39), and NN2211.
GLP-1(7-37) and GLP-1(1-37) were obtained from L. Thim (Novo Nordisk);
exendin(9-39) was purchased from Bachem (Bissendorf Biochemicals, Ham-
burg, Germany). High-performance liquid chromatography analyses of all
peptides claim 90% purity. Peptides were dissolved in sterile isotonic saline
to which 1% bovine serum albumin (BSA) was added (Fraction V, #735 086;
Boehringer Mannheim, Mannheim, Germany). The GLP-1 derivative NN2211
(Arg34, Lys26-[N-(-Glu[N--hexadecanoyl])]-GLP-1[7-37]) was synthesized
according to a previously described procedure (14). The compound NN2211 is
a member of a group of pharmacologically active GLP-1 derivatives that have
long plasma half-lives (14). Thus, NN2211 is an acylated GLP-1 derivative with
a plasma half-life of 14 h in pigs. Pharmacokinetic data from rats show that
t1/2  4 h probably as a result of considerably higher endogenous DPP-IV
activity in this species (L.B.K., unpublished observations). NN2211 was
dissolved in sterile phosphate-buffered saline (50 mmol/l, pH 7.4) to a ﬁnal
concentration of either 0.1 or 1.0 mg/ml. Solutions were always made fresh 1
h before use and stored at 4°C in sterile tubes. Material from several batches
of NN2211 was used, and corrections for impurity were always performed.
Subcutaneous injections were administered using standard 1-ml syringes
equipped with 25-G needles.
Experiment 1: single dose of GLP-1. Sixteen adult male Wistar rats were
equipped with jugular intravenous catheters (Department of Pharmacology,
The Panum Institute, University of Copenhagen). Catheters were implanted
under Avertin (tribromoethanol, 200 mg/kg) anesthesia in the right jugular
vein with the tip aiming at the right atrium. After placement, the catheter was
externalized via subcutaneous tunneling to the interscapular area. Catheter
patency was secured by instillation of heparinized (1,000 IU/l) isotonic sterile
saline into the catheter before closure with a metal rod. After 7 days of
postoperative recovery, animals were housed individually in standard meta-
bolic cages (Techniplast, Gazzoda, Italy) and acclimatized over a period of 7
days to a 5-h restricted feeding scheme with access to food from 8:00 A.M.t o
1 P.M. and water ad libitum.
Seven days after initiation of the restricted feeding scheme, animals were
assigned to a random crossover dosing paradigm. Five minutes before
presentation of food, animals received an intravenous injection of GLP-1 (5,
100, or 500 g/animal). Statistical analysis of intergroup treatment variation
was carried out using factorial analysis of variance (ANOVA) followed by
Scheffe post hoc analysis.
Experiment 2: single dose of NN2211. Normal adult male Wistar rats (n 
16) and MSG-treated rats (n  16) were housed individually in metabolic
cages with free access to a rat diet and water for at least 1 week before
experimentation. Animals were kept in a 12:12 light:dark cycle, and the effect
of NN2211 on nighttime food intake was assessed by injecting animals
subcutaneously 2–3 h before lights out. Animals were left without food and
water in the period from dosing to the onset of darkness. Three doses of
NN2211 and vehicle were tested in a random crossover experiment (10, 50,
and 200 g/kg). Food and water intake and diuresis were monitored every 30
min for the ﬁrst 2 h after onset of nighttime (lights out) and ﬁnally 12 h later
at lights on (t720). All measurements were done in complete darkness with the
assistance of night vision goggles (Bausch and Lomb, Rochester, NY). The
minimum interval between experiments was 48 h. Statistical analysis of
intergroup treatment variation was carried out using factorial ANOVA fol-
lowed by Scheffe post hoc analysis.
Experiment 3: continuous administration of NN2211. Beginning 1 week
before the ﬁrst dose was administered, normal adult male Wistar rats (n  16)
and MSG-treated rats (n  16) were housed individually in metabolic cages
with free access to a rat diet and water. Animals were kept on a 12:12
light:dark cycle, and the subchronic effect of two daily subcutaneous injec-
tions of NN2211 or vehicle on body weight, food and water intake, diuresis,
and feces excretion was monitored. All parameters were measured between 9
and 11 A.M. while animals received their morning dose. On the basis of daily
food intake, animals were stratiﬁed to different treatment groups ensuring
comparable baseline values for food and water intake. Animals received two
daily injections of NN2211 (100 or 200 g/kg b.i.d.) at 8:00 A.M. and 7:00 P.M.
throughout a 10-day period followed by a 5-day drug-free recovery period.
Animals were weighed every morning (between 9 and 11 A.M.) together
with measurement of daily food and water intake as well as diuresis and feces
excretion. At day 0, orbital blood samples were taken from all animals before
the ﬁrst dose was administered. Further orbital blood samples were taken at
day 7 and 14 (i.e., during and after treatment with NN2211). At the ﬁnal day of
experimentation, animals were decapitated and trunk blood was collected as
described. Different dose administrations were conducted in two separate
experiments, each with its own vehicle-treated control groups. Data from
these control groups were pooled.
Statistical analysis of effect of treatment on body weight, food and water
intake, diuresis, and feces excretion was carried out using factorial ANOVA
followed by Bonferroni correction for multiple comparison. Biochemical data
from plasma samples were analyzed using factorial ANOVA followed by
Fisher’s or Scheffe’s post hoc analysis.
Experiment 4: effect of subchronic NN2211 treatment on energy ex-
penditure and body composition. Twenty-four 12-week-old male rats were
used in this study. The rats were housed individually in a temperature- (20°C)
and light-controlled environment (12:12 light:dark cycle; lights on from 7:00
A.M.) with free access to food and water for at least 7 days before experimen-
tation. The rats were stratiﬁed into three groups (G1, G2, and G3) according
to weight 3 days before study start (n  7 per group). The rats in G1 and G3
were treated with vehicle, and the rats in G2 were treated with NN2211 (200
g/kg b.i.d.). The rats in G1 and G2 had free access to food and water during
the 7-day treatment period, whereas the rats in G3 were “single” pair fed after
the rats in G2. Body weight and food and water intake were recorded daily. By
the end of the study (day 7), oxygen consumption and body composition were
determined by indirect calorimetry and DEXA, respectively. Likewise, blood
samples were collected for determination of hematocrit as well as for plasma
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DEXA. Body composition was determined by DEXA (pDEXA Sabre, Stratec
Medizintechnic; Norland Medical Systems, Pho ¨rzheim, Germany). The instru-
ment settings used were as follows: a scan speed of 40 mm/s, a resolution of
1.0  1.0 mm, and automatic/manual histogram width estimation. The
coefﬁcient of variation as assessed by 10 repeated measurements (with
repositioning of the rat between each measurement) was 3.48, 3.17, and 3.73%
for bone mineral content, lean tissue mass, and fat tissue mass, respectively.
By the end of the study (day 7), the rats were killed. The carcasses were stored
in plastic bags at 	20°C before determination of body composition; which
was determined on defrosted carcasses.
Indirect calorimetry. Oxygen consumption, CO2 production, EE, and the
respiratory exchange ratio (RER) were determined by indirect calorimetry
(Oxymax System; Columbus Instruments, Columbus, OH). The rats (n  1 per
chamber) were placed in airtight acrylic chambers (10.5 l). Oxygen and CO2
concentrations in the chamber in- and outlet gas were determined simulta-
neously every 20.25 min over a period of 4.4 h. Instrument settings used were
as follows: a gas ﬂow rate of 1.86 l/min, settle time of 90 s; measure time of
40 s, and system recalibration for each eight-chamber measuring cycle. By the
end of the study (day 7), the nonfasted rats were subjected to indirect
calorimetry (from 8:00 A.M. 1:00 P.M.). In contrast to the previous 6 days, the
nonfasted rats did not receive NN2211 between 7:30 and 8:30 before indirect
calorimetry. On the day of indirect calorimetry, the rats received treatment at
9:30—after four pretreatment measurements. The rats had no access to food
or water during their stay in the acrylic chamber. The indirect calorimetric
measurements were performed over 3 days. As a “positive” instrument
control, every day included a reference animal “treated” with the EE increas-
ing compound 2,4-dinitrophenol (DNP, Sigma). On the basis of the measure-
ments of O2 and CO2 in the chamber in- and outlet gas, estimates of O2
consumption, CO2 production, EE, and RER were calculated.
Blood sampling and biochemical assays
Blood sampling. Orbital blood samples were obtained by puncture of the
orbital venous plexus with glass capillary tubes. Samples were taken in
standard heparinized EDTA (0.18 mol/l) glass tubes (Vacutainer) to which
aprotinin (1,500 KIE/ml) and bacitracin (3%) were added. After sampling,
tubes were kept on ice before being centrifuged (4°C at 5,000g for 10 min), and
the resulting plasma was stored at 	80°C before being analyzed. Trunk blood
was obtained by decapitating animals and sampling into heparinized (500
IU/tube) glass tubes to which aprotinin (1,500 KIE/ml) and bacitracin (3%)
were added. Glycerol and FFA concentrations were determined in EDTA (0.18
mol/l) plasma containing 1% NaF (wt/vol).
Plasma glucose. Plasma glucose was measured on a standard COBAS
analyzer (Toxicology Projects & Planning, Novo Nordisk, Copenhagen, Den-
mark).
Plasma leptin. Plasma leptin was measured using a commercially available
mouse leptin enzyme-linked immunosorbent assay kit (Crystal Chemical,
Chicago, IL), showing 95% cross-reactivity to rat leptin.
Plasma biochemistry. Orbital blood samples (days 0, 7, and 14) were taken
from rats that were receiving 100 g/kg b.i.d. NN2211 and a set of correspond-
ing vehicle-treated animals. Plasma values of sodium, TG, cholesterol, creat-
inine, carbamide, and total protein were measured on a standard COBAS
analyzer. FFA and glycerol were measured on a standard Hitachi Automatic
analyzer.
Plasma potassium. Orbital blood samples (days 0, 7, and 14) were taken
from rats that were receiving 200 g/kg b.i.d. NN2211 and a set of correspond-
ing vehicle-treated animals. Blood was collected in heparinized glass tubes
(Vacutainer), and the potassium content in resulting plasma was measured
potentiometrically with an ion selective probe on a standard COBAS analyzer.
RESULTS
Experiment 1
Effects of a single dose of GLP-1 on feeding behav-
ior. Acute intravenous administration of high doses of
GLP-1 (100 and 500 g/animal) decreased food intake at 30
and 60 min after onset of feeding period in rats that were
kept on a restricted feeding scheme (Fig. 1). The anorectic
effect of the highest dose of GLP-1 (500 g/animal) was
completely abolished by previous administration of 100 g
of exendin(9-39) (6.1 
 0.4 vs. 5.9 
 0.3 g). Also, the
biologically inactive peptide GLP-1(1-37) (500 g/animal)
had no acute effect on food intake (6.1 
 0.4 vs. 6.2 

0.3 g). Water intake was similarly decreased in rats that
were receiving an intravenous injection of GLP-1, and the
pharmacological characteristics of water consumption
mirrored that of feeding.
Intravenous administration of GLP-1 also affected diure-
sis. Water excretion was markedly and dose-dependently
increased in rats that were receiving intravenous bolus
injections of GLP-1 (100 and 500 g/animal; Fig. 2). The
effect displayed pharmacological speciﬁcity in as much it
was not elicited by 500 g/animal GLP-1(1-37). However,
an attempt to antagonize the diuretic effect of 500 go f
GLP-1 with exendin(9-39) (100 g/animal) was only partial-
ly successful. Thus, exendin(9-39) completely abolished
anorectic GLP-1 actions, whereas the diuretic actions of
500 g GLP-1 were only partially abolished (Fig. 2).
Experiment 2
Effects of a single dose of NN2211 on feeding behav-
ior in rats. The acute effects of three doses of NN2211 on
nighttime feeding were tested in a random crossover
experiment (10, 50, and 200 g/kg). The dose dependence
of NN2211 on overnight food intake in normal rats is
illustrated in Fig. 3. Two hours after onset of the feeding
FIG. 1. Single intravenous infusions of GLP-1(7-37) cause dose-depen-
dent anorexia in rats that are kept on a restricted feeding schedule.
Food intake over the initial 30 min of the feeding session was recorded
for all doses tested (5, 100, and 500 g/rat). *, statistically signiﬁcant
differences from vehicle-treated animals (P < 0.05 as determined by
ANOVA followed by Scheffe’s post hoc analysis).
FIG. 2. Acute intravenous administration of GLP-1 causes profound
diuresis. *, statistically signiﬁcant difference from all other groups; a,
statistically signiﬁcant differences from vehicle-treated animals (P <
0.05 as determined by ANOVA followed by Scheffe’s post hoc analysis).
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intake (3.8 
 0.3 vs. 5.2 
 0.3 g of food). The following
morning (t720), both 50 and 200 g/kg signiﬁcantly inhib-
ited food intake in normal rats (control: 22.4 
 0.7; 50
g/kg: 16.3 
 0.7; 200 g/kg: 8.7 
 1.3 g of food) as well as
in MSG-treated rats (control: 12.5 
 1.9; 50 g/kg: 10.0 

1.0; 200 g/kg: 5.8 
 0.7 g of food).
Effects of a single dose of NN2211 on water intake
and diuresis. In the same experiment, water intake and
diuresis was monitored (Fig. 3). Both 50 and 200 g/kg
NN2211 signiﬁcantly inhibited overnight (t720) water in-
take in normal and MSG-treated rats (vehicle: 32.8 
 2.0;
50 g/kg: 21.1 
 1.1; 200 mg/kg: 11.5 
 2.5 g; vehicle-MSG:
21.2 
 2.5; MSG-50 g/kg: 17.1 
 1.9; MSG-200 g/kg:
11.5 
 1.3 ml; P  0.05 as determined by ANOVA followed
by post hoc Scheffe’s analysis). In contrast, the highest
dose of NN2211 (200 g/kg) signiﬁcantly increased diure-
sis in both normal and MSG-treated rats (vehicle: 7.6 
 0.3;
200 g/kg: 13.7 
 1.7; vehicle-MSG: 9.0 
 1.2; MSG-200
g/kg: 12.3 
 0.9 ml; P  0.05 as determined by ANOVA
followed by post hoc Scheffe’s analysis).
Experiment 3
Effect of subchronic administration of NN2211 on
food intake and body weight. Two daily injections of
NN2211 to adult male Wistar rats dose-dependently de-
creased body weight over the entire 10-day treatment
period with signiﬁcant differences obtained with the 200
g/kg b.i.d. dosing regimen between treatment days 7 and
14 (Fig. 4). Loss in body weight was preceded by de-
creased food and water intake and increased diuresis (Fig.
5). Food intake was signiﬁcantly lower during the initial 3
days of treatment for normal animals that were treated
with 100 g/kg b.i.d. (data not shown). Thereafter, the
anorectic effect of this low dose was no longer statistically
signiﬁcant. In animals that were treated with 200 g/kg
b.i.d., food intake was signiﬁcantly lower throughout the
10-day treatment period. After cessation of the treatment,
food intake normalized within a few days and body weight
FIG. 3. Single subcutaneous injections of NN2211 dose-dependently
inhibit food and water in both normal and MSG-treated rats. Dose-
response curves for 720 min of food and water intake as well as diuresis
in normal and MSG-treated rats receiving a single subcutaneous dose
of NN2211. *P < 0.05 versus vehicle (ANOVA followed by Scheffe’s post
hoc analysis);
aP < 0.05 versus 10 g/kg NN2211 (ANOVA followed by
Scheffe’s post hoc analysis);
bP < 0.05 versus 50 mg/kg NN2211
followed by Scheffe’s post hoc analysis).
FIG. 4. Subchronic administration of NN2211 dose-dependently de-
creases body weight in both normal adult male Wistar rats and MSG-
treated rats. Animals received two daily subcutaneous injections of
NN2211 (100 or 200 g/kg) or vehicle for 10 days followed by a 5-day
recovery period. Body weight was monitored each morning. Values are
mean  SE (n  5–8). *, signiﬁcant difference from relevant vehicle-
treated control as determined by ANOVA followed by Bonferroni
multiple comparison post hoc analysis.
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NN2211-treated animals. Shaded areas reﬂect baseline values obtained from all animals in the group throughout the week before onset of
treatment.
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(Fig. 5).
Similar effects of NN2211 treatment on food intake were
seen in obese MSG-treated rats. Thus, two daily injections
of 200 g/kg NN2211 signiﬁcantly decreased body weight
throughout the 10-day treatment period, whereas the 100
g/kg b.i.d. dosing regimen displayed a trend toward
weight reduction without reaching statistical signiﬁcance.
Also, food intake was signiﬁcantly lower in MSG-treated
animals that were treated with 200 g/kg b.i.d. NN2211.
Effect of subchronic administration of NN2211 on
water intake, diuresis, and feces excretion. In con-
trast to food intake, water intake was lower in NN2211-
treated animals only at the initial days of treatment,
because from day 4 onward, NN2211-treated groups dis-
played considerably higher water intake than correspond-
ing vehicle-treated groups (Fig. 5). However, these effects
were not statistically signiﬁcant and had no impact on
long-term body ﬂuid homeostasis (see below).
In normal rats that were receiving 100 g/kg b.i.d.
NN2211, increased diuresis was accompanied by in-
creased water intake from treatment day 2 onward to
cessation of dosing (data not shown). In animals that were
receiving 200 g/kg b.i.d., however, ﬂuid homeostasis was
severely affected during the ﬁrst 2 days of dosing, because
a state of very low water intake coexisted with markedly
increased diuresis (Fig. 5). For normal rats that were
treated with 200 g/kg b.i.d., apparent ﬂuid balance with
water consumption and diuresis at levels similar to vehi-
cle-treated animals occurred from day 4 onward. Despite
marked increasing effects on urinary water excretion,
plasma sodium and potassium remained unaffected in
animals that were treated with 200 g/kg b.i.d. NN2211
(Table 1). Also, plasma variables reﬂecting renal function
(creatinine, carbamide, and total protein) were unaffected
by NN2211 treatment (Table 1). Feces excretion was
followed in normal animals that were receiving 200 g/kg
b.i.d. and was observed to decrease during administration
of NN2211 coincident with the decrease in food intake
(Fig. 5).
In MSG-treated rats, NN2211 treatment (both 100 and
200 g/kg b.i.d.) induced a statistically signiﬁcant reduc-
tion of water intake and increased diuresis, leading to an
initial negative water balance (Fig. 5). The compensatory
water homeostatic mechanisms were clearly more undu-
lating in MSG-treated animals that were treated with 200
g/kg b.i.d. because they went through a phase character-
ized by polyuria and hyperdipsia from day 3 to day 6
before full compensation was obtained (Fig. 5). In the
recovery phase after cessation of the treatment, the
slightly lower water intake that accompanied lower food
intake at the end of the NN2211 treatment period rapidly
returned to control levels. As with normal animals, MSG-
treated animals’ plasma electrolyte levels were unaffected
by NN2211 treatment both during and after cessation of
drug administration (Table 1).
Experiment 4
Effect of subchronic administration of NN2211 on
EE, body composition, food intake, and body
weight. As seen in experiment 3, 7 days of NN2211
treatment signiﬁcantly lowered body weight (373.3 
 14.7
vs. 417.3 
 15.3 g), and the body weights in the pair-fed
group were reduced similarly (378.5 
 10.5). After 7 days
of treatment, EE was considerably lower in both NN2211
and pair-fed animals (control 1,775 
 39; pair fed 1,634 

49; NN2211 1,641 
 27 kcal/h; n  6–7, average of 3-h
measurements). However, when EE was expressed as
oxygen consumption per kilogram of body mass, no such
differences were seen throughout the observation period
(Fig. 6). Also, the RER was unaffected by 7 days of NN2211
treatment (Fig. 7). In contrast, pair-fed animals displayed a
switch toward lipid metabolism, probably reﬂecting that
these animals had been starved for a longer period of time
before the onset of experiment.
Body composition analysis was carried out using a
DEXA scanner specialized for small animals. Treatment
with NN2211 reduced body weight by affecting both lean
and adipose tissue mass, although the loss of fat mass did
not quite reach statistical signiﬁcance (Table 2). However,
the percentages of lean and adipose tissue mass of total
body weight changed in neither NN2211-treated nor pair-
fed animals. The hydration status after 7 days of treatment
was further assessed by measuring the hematocrit, and
pair-fed animals displayed signiﬁcant hemoconcentration
TABLE 1
NN2211 treatment (200 g/kg BID) exerts no adverse effects on plasma glucose, potassium, sodium, and plasma variables that reﬂect
renal function (creatinine, carbamide, and protein)
Normal vehicle
(n  8)
Normal NN2211
(n  8)
MSG vehicle
(n  4)
MSG NN2211
(n  8)
Treatment values (day 7)
Glucose (mmol/l) 6.7 
 0.5 6.9 
 0.2 6.1 
 1.0 6.7 
 0.3
Potassium (K
) (mmol/l) 4.6 
 0.3 4.2 
 0.1 4.3 
 0.2 4.1 
 0.1
Sodium (Na
) (mmol/l) 136.5 
 0.4 136.9 
 0.6 138.2 
 0.5 139.0 
 0.3
Creatinine (mmol/l) 87.6 
 1.7 75.6 
 2.4 76.3 
 3 77.5 
 1.9
Carbamide (mmol/l) 8.4 
 0.2 8.9 
 0.5 7.3 
 0.3 8.5 
 0.3
Protein (g/l) 64.0 
 1.2 63.4 
 1.2 65.4 
 1.0 64.1 
 0.6
Recovery-phase values (day 14)
Glucose (mmol/l) 6.8 
 0.1 6.4 
 0.2 5.7 
 1.0 6.2 
 0.2
Potassium (K
) (mmol/l) 5.2 
 0.5 4.6 
 0.3 4.3 
 0.4 5.0 
 0.1
Sodium (Na
) (mmol/l) 139.5 
 0.6 138.7 
 0.4 141.4 
 0.7 140.2 
 1.2
Creatinine (mmol/l) 85.3 
 1.2 81.9 
 1.4 85.0 
 1.1 90.4 
 3.9
Carbamide (mmol/l) 7.9 
 0.2 8.0 
 0.1 7.9 
 0.3 7.3 
 0.2
Protein (g/l) 67.2 
 1.2 65.0 
 0.6 66.3 
 0.7 64.3 
 0.7
Data are means 
 SD.
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NN2211-treated animals (ad libitum 45.6 
 0.8; NN2211
47.0 
 0.9; pair-fed 49.1 
 0.9%; n  7).
Effect of subchronic administration of NN2211 on
plasma glucose and lipids. A number of biochemical
plasma variables were assessed in animals that were
subjected to either 7 or 10 days of NN2211 treatment
(experiments 3 and 4). Data obtained from experiment 3
showed no effect of NN2211 on glucose and total choles-
terol (Tables 1 and 3). However, subchronic administra-
tion of NN2211 lowered plasma TG levels in both normal
and MSG-treated rats, probably a direct consequence of
lowered food intake (Table 1). Blood obtained from ani-
mals in experiment 4 was analyzed for cholesterol, FFA,
and glycerol. As in experiment 3, total cholesterol was
unaffected but animals that were treated with NN2211 (200
g/kg b.i.d.) displayed a tendency toward lower plasma
levels of FFA in comparison with both pair-fed and ad
libitum–fed control animals (NN2211, 136 
 16; pair-fed,
195 
 18; FFA, 192 
 43 nmol/l; n  6–7).
Because of different sampling techniques required for
potassium analysis (heparinized and not EDTA tubes), this
parameter was measured together with leptin in animals
that were receiving 200 g/kg b.i.d. Plasma leptin levels
decreased in both normal and MSG-treated animals during
NN2211 treatment (200 g/kg b.i.d.; Fig. 8).
DISCUSSION
In contrast to earlier beliefs (7,8), intravenous administra-
tion of native GLP-1 signiﬁcantly decreased food and
water intake in rats via a peripherally accessible site.
However, the current use of much higher doses of GLP-1
may well explain this discrepancy (500 g/animal instead
of 10 g/animal). GLP-1 is primarily degraded by the
circulating protease DPP-IV (EC 3.4.14.5), and activity
levels of this circulating enzyme are very high in the rat
compared with other mammals such as pigs and humans
(5,15–17). Thus, plasma half-life of GLP-1 in rats is very
short.
Like native GLP-1, peripheral administration of a single
dose of NN2211 signiﬁcantly inhibited nighttime food
intake in rats. The effect was not readily recognized during
the initial 120 min of the dark phase, probably reﬂecting
protracted pharmacokinetic mobilization from subcutane-
ous injection depot as demonstrated previously in female
rats (18). Pharmacokinetic characterization of this GLP-1
derivative in humans revealed plasma half-lives of active
GLP-1 derivative of 14 h, which is considerably longer
than the half-life of endogenous GLP-1 (1.2 h) (19). Pre-
liminary studies of NN2211 half-life in the rat have shown
somewhat shorter values (single subcutaneous bolus: t1/
2  4 h), probably because of aforementioned high activity
levels of DPP-IV (L.B.K., unpublished observations).
The site of the anorectic action elicited by peripheral
administration of GLP-1/NN2211 is different from the site
that elicits anorexia in response to intracerebroventricular
administration of GLP-1, i.e., it does not involve MSG-
sensitive parts of the hypothalamus (12). However, partici-
pation of both central and peripheral sites in GLP-1–
induced anorexia should be considered because a recent
study showed that radiolabeled GLP-1 readily gains access
to the central nervous system (18). The nucleus of the
solitary tract is adjacent to the blood-brain barrier–free
area postrema, and a number of studies have shown that
peripheral administration of neuropeptides not only labels
the area postrema but also diffuses into the adjacent
regions (20). Such a mechanism is supported by our recent
observations from rats that were implanted with GLP-1–
synthesizing tumors in which anorexia develops irre-
spective of subdiaphragmatic vagal transection (P.J.L.,
unpublished observations). Thus, it seems likely that the
anorectic effect of peripheral GLP-1 is mediated via a
peripherally accessible site located either in the brainstem
or on vagal afferents. In rats, the inhibitory actions of
GLP-1 on gastric motility is mediated via the vagus nerve
(11), but also direct inhibition of gastrin secretion as well
as stimulation of somatostatin release may affect gastric
emptying (21,22). Obviously, delayed gastric emptying coun-
FIG. 6. Oxygen consumption was determined by indirect calorimetry by
the end of the study (day 7). The rats received treatment at time point
0 (10:00 A.M.). The rats had no access to food or water while being
subjected to indirect calorimetry. On each day of experimentation, an
animal treated with the chemical uncoupler 2,4-dinitrophenol (DNP)
was included as a “positive” instrument. The results are expressed as
mean  SE
FIG. 7. The RER was determined by indirect calorimetry by the end of
the study (day 7). The rats received treatment at time point 0 (10:00
A.M.). The rats had no access to food or water while being subjected to
indirect calorimetry. On each day of experimentation, an animal
treated with the chemical uncoupler 2,4-dinitrophenol (DNP) was
included as a “positive” instrument. The results are expressed as
mean  SE.
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sequent beneﬁcial glucose homeostatic effects. Decreased
gastric motility may also be part of a premature inhibition
of further ingestion as it constitutes a prandial satiety
signal mediated via vagal stretch receptive nerve ﬁbers.
A full analysis of NN2211 effects on the feeding pattern
(meal size, intermeal interval, etc.) was not carried out,
but preliminary data suggest that acute as well as sub-
chronic peripheral administration of NN2211 reduces meal
size similar to what is known for other gastrointestinal
hormones, such as CCK (22,23; P.J.L., unpublished obser-
vations). It has been suggested that signals that modify
food intake via diminishing meal size are both direct and
indirect (23). Direct signals are elicited when nutrients
gain contact to various segments of the gastrointestinal
tract, whereas indirect signals arise from other sources
than the gastrointestinal tract. Indirect signals modify the
gain of direct signals, thereby inﬂuencing the efﬁcacy of
acute meal-terminating signals. Thus, GLP-1 represents a
direct signal that arises from fat and carbohydrate contact
with duodenal and jejunal lumen. The signal to ileal L-cells
may also be hormonal in as much as gastric inhibitory
peptide links the proximal small intestine with more distal
segments. GLP-1 released from the distal ileum is foremost
an incretin with actions on pancreatic insulin secretion
(and inhibition of glucagon secretion), but it also has
actions as an ileal brake, reducing gastric emptying and
subsequently halting nutrient delivery to absorptive por-
tions of the gastrointestinal tract (24). According to the
proposed model of direct and indirect meal-terminating
signals, it seems plausible that peripherally released GLP-1
interacts with leptin-sensitive sites in the brain stem (25).
With the advent of a long-acting GLP-1 derivative, future
studies of additive pharmacological effects of leptin and
NN2211 will help to elucidate whether leptin exerts syn-
ergy with GLP-1 as is seen for another gastrointestinal
tract hormone, CCK (26,27).
In the central nervous system, there is evidence that two
independent GLP-1–sensitive systems mediate the anorec-
tic effects of centrally applied GLP-1. Firm evidence as-
cribes ascending GLP-1–containing nerve ﬁbers that
originate in the caudal part of the nucleus of the solitary
tract as mediators of visceral illness (28,29). However, the
precise location(s) of the central GLP-1 receptors involved
in this mechanism is unknown (28). Nonaversive reduc-
tion of food intake is elicited upon direct injection of GLP-
1 into the hypothalamic paraventricular nucleus (13,30).
The regulatory role of both intestinal and central ner-
vous system GLP-1 as either hormonal or neurotransmitter
mediators of satiety has been questioned by observations
from GLP-1 receptor null mutant mice (GLP-1R 	/	)
because these mice do not display an obese phenotype
(31). However, initial statements about the lack of GLP-1R
function in regulation of satiety are incorrect, because
further evidence that GLP-1 has a role as an acute short-
term mediator of satiety has actually been gained from
studies on GLP-1R(	/	) mice. Careful analysis of the data
presented by Scrocchi et al. (32) clearly demonstrates that
GLP-1R(	/	) mice terminate the initial feeding period of
the dark phase signiﬁcantly later than wild-type animals,
resulting in increased food intake during the initial4ho f
the dark phase. In GLP-1R(	/	) mice, other postprandial
satiety factors probably take over the meal-terminating
role of GLP-1 with resulting unaffected total caloric intake.
So far, no loss of function mutations in the human GLP-1
receptor has been reported, but the therapeutically inter-
esting question is whether long-term activation of periph-
erally accessible GLP-1 receptors constitutes a potential
weight-reducing principle.
Using a novel long-acting GLP-1 derivative, NN2211, we
TABLE 2
Body composition
Ad libitum–fed vehicle Pair-fed vehicle NN2211
Body weight (g) 417.3 
 15.3 378.5 
 10.6† 373.3 
 14.7†
BMC (g) 10.2 
 0.8 10.2 
 0.3 9.8 
 0.6
Bone area (cm
2) 70.4 
 6.4 75.1 
 2.0 68.7 
 3.0
BMD (g/cm
2) 0.145 
 0.009 0.137 
 0.004 0.143 
 0.002
Lean tissue mass (g) 372.3 
 18.9 321.2 
 8.2† 339.6 
 17.4†
Lean tissue mass (% of BW) 89.2 
 2.5 84.9 
 2.5* 91.0 
 3.5
Fat tissue mass (g) 35.5 
 9.0 45.9 
 9.7 24.6 
 13.1
Fat tissue mass (% of BW) 8.5 
 2.2 12.1 
 2.3* 6.5 
 3.3
Data are mean 
 SD. Body composition was determined by DEXA at the end of the study (day 7). The results are given as absolute values
(grams) and as % of body weight (BW). *P  0.05 versus ad libitum–fed vehicle; †P  0.01 versus ad libitum–fed vehicle.
TABLE 3
Plasma lipids: NN2211 treatment (100 g/kg b.i.d.) reduces plasma triglyceride levels in both normal lean Wistar and MSG-treated rats
Normal vehicle Normal NN2211 MSG vehicle MSG NN2211
Treatment values (day 7)
Cholesterol (mmol/l) 1.98 
 0.1 1.90 
 0.1 2.07 
 0.1 1.81 
 0.8
Triglyceride (mmol/l) 1.58 
 0.1 1.21 
 0.3*† 2.27 
 0.3*† 1.49 
 0.1*
Recovery phase values (day 14)
Cholesterol (mmol/l) 1.89 
 0.1 1.98 
 0.1 2.14 
 0.1 1.98 
 0.1
Triglyceride (mmol/l) 1.62 
 0.2 1.29 
 0.1 1.93 
 0.2† 1.89 
 0.2†
Data are expressed as mean 
 SE (n  8 in all groups). *P  0.05 versus control within the group (ANOVA followed by Fisher’s post hoc
analysis); †P  0.05 versus respective non-MSG control (ANOVA followed by Fisher’s post hoc analysis).
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chronic administration of a GLP-1 agonist confers pro-
found weight loss in both normal lean rats and in obese
MSG-treated rats. Subchronic administration of NN2211
lowered plasma triglyceride levels in both normal and
MSG-treated rats, probably reﬂecting enhanced peripheral
postprandial insulin actions. However, NN2211-treated
animals also underwent a mild state of catabolic degrada-
tion of adipose tissue stores inasmuch as leptin levels
decreased in both normal and MSG-treated rats. Thus, the
decreased levels of circulating triglyceride levels may have
been the direct consequence of lowered food intake.
Analysis of body composition by DEXA scanning was
unable to reveal a signiﬁcant loss of body fat in response
to NN2211 or pair feeding. However, the interanimal
variation, limited group sizes, and lack of instrument
precision gave rise to relatively large standard deviations
despite numerous repeated measurements. Thus, the lack
of statistical signiﬁcance of the observed drop in body
adiposity of NN2211-treated animals may be due to a
simple type 2 statistical error. First impressions of body
weight curves and matched food intake suggest that GLP-1
agonists may enhance EE in addition to their anorectic
effects. Measures of EE clearly showed that NN2211-
treated and pair-fed animals had similar metabolic rates
and body weights. However, the persistent weight loss and
the apparent lack of rebound hyperphagia upon cessation
of the NN2211 treatment are more enigmatic. Although
long-term pharmacokinetic data are unavailable, it seems
possible that the dosing regimen of NN2211 used in this
study gives rise to accumulation of the compound in a
subcutaneous compartment, thereby resulting in pro-
tracted slow release of the active GLP-1 analogue. Also,
NN2211 had no impact on substrate utilization, ruling out
that major shift toward fatty acid oxidation occurs during
NN2211 treatment. It is worth keeping in mind that rodent
and human substrate mobilization may vary considerably.
Thus, future studies of EE in NN2211-treated humans are
needed to elucidate fully the impact of this compound on
human energy homeostasis.
A number of studies have investigated the potential
anorectic effects of short-term intravenous GLP-1 infusion
to human volunteers (24 h). Both nonobese and obese
humans respond to GLP-1 infusion by reducing their
caloric intake without concomitant presence of gastroin-
testinal discomfort or increased equivalents of malaise
(1,3). Subchronic administration of relatively high doses of
the GLP-1 analogue exendin-4 to diabetic rodents de-
creases food intake and lowers body weight (33–35). Greig
et al. (33) included a control group of normal-weight
nondiabetic mice, in which both food intake and body
weight remained unaffected by administration of 24 nmol/
kg per day, suggesting that the anorectic effect may de-
pend on increased plasma glucose levels or impaired
insulin sensitivity. GLP-1–induced anorexia is not medi-
ated via pancreatic insulin secretion because normal rats
displayed full sensitivity to NN2211 during euglycemia,
when GLP-1 has no insulinotropic action. Extensive stud-
ies with NN2211 have shown that this derivative as native
GLP-1 is incapable of causing serious hypoglycemia (36).
Also, MSG-treated rats were fully sensitive to the anorectic
action of NN2211 despite their well-known decreased
peripheral insulin sensitivity (37,38). It is interesting to
note that both circulating and postprandial levels of active
GLP-1(7-36)amide are decreased in obese humans (39). In
particular, obese individuals seem to have a selective
attenuation of carbohydrate-induced postprandial GLP-1
secretion, and this defect may be related to the dyslipide-
mia experienced by most obese individuals because the
degree of impaired GLP-1 release is tightly correlated to
the circulating levels of nonesteriﬁed fatty acids (40).
Therefore, acute regulation of feeding behavior in obese
individuals may involve a weaker-than-normal postpran-
dial GLP-1 satiety signal. In conjunction with carbohydrate
ingestion, insulin-induced leptin secretion is markedly
increased in comparison to levels seen during fat ingestion
(41). Thus, lower-than-normal postprandial GLP-1 release
in obese individuals may lead to an insufﬁcient insulin
release, causing both impaired glucose tolerance and
lower leptin secretion.
In conclusion, we showed that peripheral administra-
tion of GLP-1 and a long-acting derivative hereof, NN2211,
induce anorexia together with lowered water intake and
increased diuresis. Furthermore, NN2211 confers lasting
and reversible anorexia with accompanying weight loss
and reduction of body adiposity. As seen for many other
anorectic agents, NN2211 causes a moderate drop in total
EE proportional to the induced weight loss. However, no
change in substrate utilization was seen. Despite initial
effects on water intake and diuresis, NN2211 administra-
tion has no debilitating effects on body water homeostasis.
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